Use este identificador para citar ou linkar para este item: http://www.repositorio.ufop.br/jspui/handle/123456789/11066
Título: Determination of intestinal permeability using in situ perfusion model in rats : challenges and advantages to BCS classification applied to digoxin.
Autor(es): Caldeira, Tamires Guedes
Ruiz Picazo, Alejandro
Lozoya Agullo, Isabel
Guimarães, Dênia Antunes Saúde
González Álvarez, Marta
Souza, Jacqueline de
González Álvarez, Isabel
Bermejo, Marival
Palavras-chave: Intestinal absorption
Digoxin
Biopharmaceutic
Data do documento: 2018
Referência: CALDEIRA, T. G. et al. Determination of intestinal permeability using in situ perfusion model in rats : challenges and advantages to BCS classification applied to digoxin. International Journal of Pharmaceutics, v. 551, n. 1–2, p. 148-157, nov. 2018. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0378517318306732?via%3Dihub>. Acesso em: 25 fev. 2019.
Resumo: The purpose of this work was to describe the closed loop in situ perfusion method in rats and to compare the difficulties and advantages with other methods proposed by regulatory agencies for BCS classification and finally to illustrate its application to evaluate the permeability of digoxin at relevant clinical concentrations. Digoxin was evaluated at two concentration levels: 1.0 μg/ml (with and without sodium azide 65.0 μg/ml) and 6.0 μg/ ml. These concentrations correspond to the ratio of the highest dose strength (0.25 mg) and the highest single dose administered (1.5 mg) and the 250 ml of water. In situ closed loop perfusion studies in rats were performed in the whole small intestine and also in duodenum, jejunum and ileum segments to evaluate the relevance of Pgp secretion in the overall permeability. A kinetic modelling approach involving passive permeation and efflux transport mechanism allowed the estimation of the passive diffusional component and the Michaelis-menten parameters. The estimated Km value demonstrated that at clinical luminal concentrations the efflux process is not saturated and then it could be inhibited by other drugs, excipients or food components leading to the already reported clinical drug-drug and drug-food interations. The present data confirms from a mechanistic point of view these interactions.
URI: http://www.repositorio.ufop.br/handle/123456789/11066
Link para o artigo: https://www.sciencedirect.com/science/article/pii/S0378517318306732
DOI: https://doi.org/10.1016/j.ijpharm.2018.09.022
ISSN: 0378-5173
Aparece nas coleções:DEFAR - Artigos publicados em periódicos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_DeterminationIntestinalPermeability.pdf
  Restricted Access
617,88 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.